Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method
Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method
复制标题
DOI：
10.1016/j.cmi.2018.02.021
复制
发表时间：
2018-11-01
影响因子：
14.2
通讯作者：
Guinea, J.
中科院分区：
文献类型：
--
作者：
Arendrup, M. C.;Meletiadis, J.;Guinea, J.
目的：Rezafungin （CD101）是一种新的长效针珠菌素，允许每周给药，目前正在进行侵袭性念珠菌病的ii期临床试验。本研究的目的是根据EUCAST方法评估rezafungin对最常见的念珠菌的体外活性。方法：对欧洲4个实验室2018株临床念珠菌进行药敏检测。同时，重复检测6株对照菌株。野生型上限（WT-ULs），定义为野生型分布结束的MIC值，根据EUCAST ecoff设置原则确定。结果：白色念珠菌的rezafungin MIC(几何MIC （GM-MIC)， MIC范围（mg/L））最低（0.016,0.002 ~ 0.125），假丝酵母菌最高（1.657,0.063 ~ 0.04）。其余物种的mic值介于0.048 ~ 0.055之间。视觉wt - ul与统计wt - ul相同，分别为：光秃c（0.125）、克鲁西c（0.125）、拟疏c(4)和热带c（0.25）。如果采用这些WT- ul分类为WT和非WT群体，则1/413 C. glabrata, 1/402 C. krusei, 1/398 C. parapsilosis和1/402 C. tropical alis分离物被归类为非WT，所有分离物均来自实验室1。对于白色念珠菌，观察到不明原因的实验室变异（WT-UL：实验室1和2为0.063-0.125，实验室3和4为0.016）。2号实验室与3号和4号实验室的3株白色念珠菌QC株的mic值也存在类似的系统差异。讨论：Rezafungin表现出与其他棘白菌素相似的物种特异性活性。最敏感的白色念珠菌临床菌株和QC菌株在实验室间存在差异，值得进一步调查。(C) 2018年欧洲临床微生物学与传染病学会。Elsevier Ltd.出版。版权所有。
Objectives: Rezafungin (CD101) is a new long-acting echinocandin allowing weekly dosing, currently undergoing phase-II clinical trials for invasive candidiasis. The aim of this study was to assess rezafungin's in vitro activity against the most frequent Candida species following the EUCAST methodology.Methods: The susceptibility of 2018 clinical Candida isolates was determined at four European laboratories. In parallel, six control strains were repeatedly tested. Wild-type upper limits (WT-ULs), defined as the MIC value where the wild-type distribution ends, were determined following the principles for EUCAST ECOFF-setting.Results: The lowest rezafungin MICs (geometric MIC (GM-MIC), MIC range (mg/L)) were observed for C. albicans (0.016, 0.002-0.125) and the highest for C. parapsilosis (1.657, 0.063->4). MICs for the remaining species were in between these values (GM-MICs 0.048-0.055). Visual and statistical WT-ULs were identical for C. glabrata (0.125), C. krusei (0.125), C. parapsilosis (4), and C. tropicalis (0.25). If adopting these WT-ULs for classification into WT and non-WT populations, 1/413 C. glabrata, 1/402 C. krusei, 1/398 C. parapsilosis, and 1/402 C. tropicalis isolates were categorized as non-WT, all of which derived from Laboratory 1. For C. albicans unexplained laboratory variation was observed (WT-UL: 0.063-0.125 in Laboratories 1 and 2 versus 0.016 in Laboratories 3 and 4). A similar systematic difference was observed comparing the MICs for the three C albicans QC strains, specifically, obtained in Laboratories land 2 with those in Laboratories 3 and 4.Discussion: Rezafungin displayed species-specific activity similar to other echinocandins. Interlaboratory variation was observed for the most susceptible species C. albicans clinical and QC strains, an observation that warrants further investigation. (C) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.